Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

Formoterol Fumarate Inhalation Solution (RLD Perforomist®) had estimated annual sales of USD 268 million in the U.S. (IQVIA MAT September 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 750.85 as compared to the previous close of Rs. 733.70. The total number of shares traded during the day was 129216 in over 5740 trades.

The stock hit an intraday high of Rs. 759.15 and intraday low of 740.25. The net turnover during the day was Rs. 96928082.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 FormoterolFumarateInhalationSolution Perforomist MylanSpecialty